GSK3B and serum lipopolysaccharide activity: Consistent with other studies showing that GSK-3 is involved in several nephrotoxicity models, including endotoxemia, ischemia, and non-cisplatin drugs [15,19,20,22], this study also provides evidence of cisplatin-induced GSK-3β activation in vivo and in vitro.